Advertisement

Tumoren

  • Rudolf Peter Wüthrich

Zusammenfassung

Es ist wohlbekannt, daß Organtransplantation mit einem erhöhten Krebsrisiko einhergeht. Krebskrankheiten treten bei immunsupprimierten Transplantierten mit größerer Inzidenz auf, verglichen mit der Normalbevölkerung (2, 6, 11, 20). Die Inzidenz variiert beträchtlich je nach geographischer Gegend und beträgt in Europa 2%, in Amerika 6% und in Australien 24%. Diese Variation wird vor allem durch die höhere Inzidenz von Hautkrebs in Gegenden mit viel Sonnenschein erklärt. Krebs kann beim Transplantierten entweder vorbestehen, kann de novo auftreten oder durch den Spender übertragen werden (15, 16).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bavinck JNB, Vermeer BJ, van der Woude FJ et al. (1991) Relation between skin cancer and HLA antigens in renal transplant recipients. N Engl J Med 325: 843CrossRefGoogle Scholar
  2. 2.
    Blohme I, Brynger H (1985) Malignant disease in renal transplant patients. Transplantation 39: 23PubMedGoogle Scholar
  3. 3.
    Hartevelt MM, Bavinck JNB, Kootte AMM, Vermeer BJ, Vandenbroucke JP (1990) Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 49: 506PubMedCrossRefGoogle Scholar
  4. 4.
    Harwood AR, Osoba D, Hofstader SL, Goldstein MB, Cardella CJ, Holecek ML, Kunynetz R, Giammarco RA (1979) Kaposi’s sarcoma in recipients of renal transplants. Am J Med 67: 759PubMedCrossRefGoogle Scholar
  5. 5.
    Kinlen LJ, Eastwood JB, Kerr DNS, Moorhead JF, Oliver DO, Robinson BHB, De Wardener HE, Wing AJ (1980) Cancer in patients receiving dialysis. Br Med J 1: 1401CrossRefGoogle Scholar
  6. 6.
    Kinlen LJ, Sheil AGR, Peto J, Doll R (1979) Collaborative United Kingdom - Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2: 1461PubMedCrossRefGoogle Scholar
  7. 7.
    Liddington M, Richardson AJ, Higgins RM, Endre ZH, Venning VA, Murie JA, Morris PJ (1989) Skin cancer in renal transplant recipients. Br J Surg 76: 1002PubMedCrossRefGoogle Scholar
  8. 8.
    Lindner A, Farewell VT, Sherrard DJ (1981) High incidence of neoplasia in uremic patients receiving long-term dialysis. Nephron 27: 292PubMedCrossRefGoogle Scholar
  9. 9.
    Mankin J, Hudson S, Barber WH, Deierhoi MH, Diethelm AG (1989) A parametric analysis of the hazard of cancer after transplantation. Transplant Proc 21: 3201PubMedGoogle Scholar
  10. 10.
    Penn I (1978) Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery 83: 492PubMedGoogle Scholar
  11. 11.
    Penn I (1982) The occurrence of cancer in immune deficiencies. Curr Probl Cancer 6(10):l–64Google Scholar
  12. 12.
    Penn I (1983) Kaposi’s sarcoma in immunosuppressed patients. J Clin Lab Immunol 12: 1–10PubMedGoogle Scholar
  13. 13.
    Penn I (1986) Kidney transplantation following treatment of tumors. Transplant Proc 18 (No 4, Suppl 3): 16Google Scholar
  14. 14.
    Penn I (1987) Cancers following Cyclosporine therapy. Transplantation 43: 32PubMedCrossRefGoogle Scholar
  15. 15.
    Penn I (1987) Cancer and Transplantation. In: Complications of Organ Transplantation. L.H. Toledo-Pereyra (ed) Immunology Series vol 32, chap. 13. Dekker, pp 237–251.Google Scholar
  16. 16.
    Penn I (1988) Secondary neoplasms as a consequence of transplantation and cancer therapy. Cancer Detect Prevent 12: 39PubMedGoogle Scholar
  17. 17.
    Penn I (1991) The changing pattern of posttransplant malignancies. Transplant Proc 23: 1101PubMedGoogle Scholar
  18. 18.
    Penn I (1993) Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 12 (6 Pt 2): S328PubMedGoogle Scholar
  19. 19.
    Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55: 742PubMedCrossRefGoogle Scholar
  20. 20.
    Sheil AGR (1986) Cancer after transplantation. World J Surg 10: 389PubMedCrossRefGoogle Scholar
  21. 21.
    Sheil AGR, Flavel S, Disney APS, Mathew TH (1985) Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc 17 (2): 1685PubMedGoogle Scholar
  22. 22.
    Shuttleworth D, Marks R, Griffin PJA, Salaman JR (1988) Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 257: 717Google Scholar
  23. 23.
    Starzl TE, Nalesnik MA, Porter KA et al. (1984) Reversibility of lymphomas and lymphopro- liferative lesions developing under cyclosporine-steroid therapy. Lancet 1: 583PubMedCrossRefGoogle Scholar
  24. 24.
    Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. (1990) Increased incidence of lymphopro- liferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323: 1723PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Rudolf Peter Wüthrich
    • 1
  1. 1.Departement für innere Medizin Abt. für NephrologieUniversitätsspital ZürichZürichSwitzerland

Personalised recommendations